Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 467
- Registration Number
- NCT06609239
- Locations
- 🇺🇸
OK Clinical Research- Site Number : 8400021, Edmond, Oklahoma, United States
🇺🇸Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007, Pittsburgh, Pennsylvania, United States
🇺🇸South Texas Medical Research Institute - TTS Research- Site Number : 8400010, Boerne, Texas, United States
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 204
- Registration Number
- NCT06557772
- Locations
- 🇺🇸
Endoscopic Reseach, Inc.- Site Number : 8400013, Orlando, Florida, United States
🇺🇸GCP Clinical Research- Site Number : 8400007, Tampa, Florida, United States
🇺🇸Treasure Valley Medical Research- Site Number : 8400006, Boise, Idaho, United States
Goal Attainment and Physical Activity in People With Hemophilia A
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT06530030
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06508489
- Locations
- 🇺🇸
City of Hope National Medical Center- Site Number : 8400003, Duarte, California, United States
🇦🇺Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇦🇺Investigational Site Number : 0360001, Melbourne, Victoria, Australia
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT06500702
- Locations
- 🇺🇸
Investigational Site Number : 8400005, El Paso, Texas, United States
Registry for Stage 2 Type 1 Diabetes
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT06481904
- Locations
- 🇺🇸
Women and Children's Hospital of Buffalo- Site Number : 8400018, Buffalo, New York, United States
🇺🇸Columbus Regional Healthcare- Site Number : 8400013, Columbus, Ohio, United States
🇺🇸Hospital of The University of Pennsylvania- Site Number : 8400021, Philadelphia, Pennsylvania, United States
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 80
- Registration Number
- NCT06454240
- Locations
- 🇺🇸
Sacramento Ear, Nose & Throat Site Number : 8400003, Roseville, California, United States
🇺🇸Modena Allergy + Asthma Site Number : 8400005, La Jolla, California, United States
🇺🇸The Allergy Group Site Number : 8400002, Boise, Idaho, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06444451
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center- Site Number : 8400018, Birmingham, Alabama, United States
🇺🇸Center for Dermatology Clinical Research- Site Number : 8400008, Fremont, California, United States
🇨🇿Investigational Site Number : 2030012, Praha, Czechia
A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 65
- Registration Number
- NCT06418607
- Locations
- 🇺🇸
Prism Research Site Number : 8400002, Saint Paul, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami Site Number : 8400001, Miami, Florida, United States
A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9
- Registration Number
- NCT06418620
- Locations
- 🇺🇸
Prism Research Site Number : 8400001, Saint Paul, Minnesota, United States